Poxvirus Vector Vaccines 🤔🤔

Yup, Poxvirus. As in smallpox. What could possibly go wrong?

This is a very short post that I threw together in about 10-15 minutes on the spur of the moment.

On my journey through the endless sea of covid vaccine case reports, I stumbled across a series of studies from the past decade or so documenting attempts to use pox viruses as vaccine delivery vectors, where they basically grafted an antigen from the targeted virus onto a dead or attenuated modified poxvirus.

Considering what we now know about what went down in these past few years, this is at least a little hair raising.

Well, at least until discovering this study, after which it felt more like acutely disturbing:

Poxvirus vectors as HIV/AIDS vaccines in humans

https://pubmed.ncbi.nlm.nih.gov/22906946/

Abstract

The RV144 phase III clinical trial with the combination of the poxvirus vector ALVAC and the HIV gp120 protein has taught us that a vaccine against HIV/AIDS is possible but further improvements are still needed. Although the HIV protective effect of RV144 was modest (31.2%), these encouraging results reinforce the use of poxvirus vectors as HIV/AIDS vaccine candidates. In this review we focus on the prophylactic clinical studies thus far performed with the more widely studied poxvirus vectors, ALVAC, MVA, NYVAC and fowlpox expressing HIV antigens. We describe the characteristics of each vector administered either alone or in combination with other vectors, with emphasis on the immune parameters evaluated in healthy volunteers, percentage of responders and triggering of humoral and T cell responses. Some of these immunogens induced broad, polyfunctional and long-lasting CD4(+) and CD8(+) T cell responses to HIV-1 antigens in most volunteers, with preference for effector memory T cells, and neutralizing antibodies, immune parameters that might be relevant in protection. Finally, we consider improvements in immunogenicity of the poxvirus vectors by the selective deletion of viral immunomodulatory genes and insertion of host range genes in the poxvirus genome. Overall, the poxvirus vectors have proven to be excellent HIV/AIDS vaccine candidates, with distinct behavior among them, and the future implementation will be dictated by their optimized immune profile in clinical trials.

So…

They had a candidate vaccine that was in a *Phase 3* clinical trial that grafted a crucial piece of the HIV glycoprotein - gp120 - onto a poxvirus. The same piece that somehow managed to find itself inside the Covid genome.

Sars-Cov-2 Kills T-Cells, Just Like HIV

Moderna Patented CANCER GENE is in Sars-Cov-2 "Spike Protein"

And boy did they seem to have big plans for this platform:

Large-scale adenovirus and poxvirus-vectored vaccine manufacturing to enable clinical trials

https://pubmed.ncbi.nlm.nih.gov/25914340/

Abstract

Efforts to make vaccines against infectious diseases and immunotherapies for cancer have evolved to utilize a variety of heterologous expression systems such as viral vectors. These vectors are often attenuated or engineered to safely deliver genes encoding antigens of different pathogens. Adenovirus and poxvirus vectors are among the viral vectors that are most frequently used to develop prophylactic vaccines against infectious diseases as well as therapeutic cancer vaccines. This mini-review describes the trends and processes in large-scale production of adenovirus and poxvirus vectors to meet the needs of clinical applications. We briefly describe the general principles for the production and purification of adenovirus and poxvirus viral vectors. Currently, adenovirus and poxvirus vector manufacturing methods rely on well-established cell culture technologies. Several improvements have been evaluated to increase the yield and to reduce the overall manufacturing cost, such as cultivation at high cell densities and continuous downstream processing. Additionally, advancements in vector characterization will greatly facilitate the development of novel vectored vaccine candidates.

I have not had a chance to start reading through a whole slew of studies documenting these Frankenvaxxes. I suspect that the details of what sorts of modifications and gene tampering they tried are going to be fascinating to say the least.

Might this be lurking in the minds of our benevolent medical overlords regarding the current pox-related developments? Imagine needing a vaccine to vaccinate against wild-type smallpox that reverted from an poxvirus vector vaccine… you can almost literally see the dollar signs in the maniacal gleam of Fauci’s eyes. It’s not as though it would be novel or trendsetting:

Vaccine-derived polio is on the rise. A new vaccine aims to stop the spread

Over the past few years, Andino and his collaborators have been developing a new oral vaccine due to the recent outbreaks of vaccine-derived polio and an influx of funding from the Bill & Melinda Gates Foundation. The novel vaccine still contains a weakened version of the virus, but it's been hobbled even further.

For now though, given the absolute reckless disregard (or deliberate malfeasance) for apocalyptic risk taking that is the unmistakable weltanschauung of Fauci & Co, it might be prudent to assume the worst until proven otherwise.

In that light, consider the excited proclamation by the HIV-pox vaccine authors that “Overall, the poxvirus vectors have proven to be excellent HIV/AIDS vaccine candidates etc.”

Not exactly reassuring…….

---

I somehow forgot to mention this study:

Safe and effective poxvirus vectors--NYVAC and ALVAC

https://pubmed.ncbi.nlm.nih.gov/7958484/

Because of course they are.